• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop immune cells that infiltrate tumors

January 30, 2017 By Sarah Faulkner

Researchers develop immune cells that infiltrate tumorsResearchers from the Okayama University have developed a group of immune cells that can infiltrate tumors and deliver viral vectors, destroying them from the inside out. The team’s work was published in the journal Scientific Reports.

The team developed the tumor-targeting technique using a human T-cell line known as HOZOT, which naturally targets human cancer cells. HOZOT cell lines are established by co-cultivating human umbilical cord blood cells and mouse stromal cells, according to the researchers. The HOZOT cells are toxic to tumors, but do not target healthy tissue.

The scientists hypothesized that the HOZOT cells could be used to carry an adenovirus that kills the tumor from the inside. They conducted trials with the targeted therapy against a variety of human cancer cells, including colon cancer, and found that the HOZOT carriers significantly reduced the viability of human cancer cells.

Additional trials in mice showed increased survival rates in those treated with the immune cells. The team noted that the HOZOT carriers appeared to stop the immune system from reacting to the adenovirus.

Many cancer patients have developed a degree of immunity to viral vectors, because cancer treatments have already been developed using viral-based drugs that target harmful tumor tissue. However, because the virus is protected by the HOZOT cells, the host’s immune system is not triggered to release neutralizing antibodies to target the virus.

“The unique cell-in-cell property of virus-loaded HOZOT cells provides a platform for selective delivery of biologics into human cancer cells, an outcome that has important implications for the treatment of human cancers,” the team wrote.

Filed Under: Featured, Immunotherapy, Oncology, Research & Development Tagged With: Okayama University

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS